Investigating how clozapine affects a specific group of patients with schizophrenia.
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-11094857
This study is looking at how the medication clozapine can help people with a specific type of psychosis called Biotype-1, by checking how their brain and body respond to the treatment, especially for those who are struggling with thinking clearly and have more severe symptoms.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11094857 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how clozapine, an effective antipsychotic medication, can uniquely benefit patients identified as Biotype-1 within the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP). By utilizing biomarkers to classify psychosis subgroups, the study aims to explore the relationship between these biological markers and the response to clozapine treatment. The approach involves analyzing the cognitive and symptomatic profiles of patients to determine how clozapine can improve their condition, particularly for those with low cognition and high symptoms. The research will involve monitoring patients' neural and physiological states to refine diagnostic and therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who fall into the Biotype-1 category, characterized by low cognition and high symptom severity.
Not a fit: Patients who do not have a diagnosis of schizophrenia or those who do not fit into the Biotype-1 classification may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with schizophrenia, particularly those who have not responded well to other medications.
How similar studies have performed: Previous research has shown promise in using biomarker-defined subgroups to tailor treatments for psychiatric conditions, suggesting that this approach could yield significant insights.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KESHAVAN, MATCHERI S. — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: KESHAVAN, MATCHERI S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.